NEXI vs. MBIO, PHAS, GOVX, ARDS, EVOK, CING, VRPX, BPTS, KTRA, and THAR
Should you be buying NexImmune stock or one of its competitors? The main competitors of NexImmune include Mustang Bio (MBIO), PhaseBio Pharmaceuticals (PHAS), GeoVax Labs (GOVX), Aridis Pharmaceuticals (ARDS), Evoke Pharma (EVOK), Cingulate (CING), Virpax Pharmaceuticals (VRPX), Biophytis (BPTS), Kintara Therapeutics (KTRA), and Tharimmune (THAR). These companies are all part of the "pharmaceutical preparations" industry.
NexImmune (NASDAQ:NEXI) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, community ranking, media sentiment, analyst recommendations, institutional ownership and risk.
Mustang Bio received 146 more outperform votes than NexImmune when rated by MarketBeat users. Likewise, 64.12% of users gave Mustang Bio an outperform vote while only 61.11% of users gave NexImmune an outperform vote.
In the previous week, NexImmune and NexImmune both had 1 articles in the media. Mustang Bio's average media sentiment score of 0.24 beat NexImmune's score of 0.00 indicating that Mustang Bio is being referred to more favorably in the news media.
NexImmune has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500.
Mustang Bio has a consensus price target of $17.25, indicating a potential upside of 4,691.67%. Given Mustang Bio's higher possible upside, analysts plainly believe Mustang Bio is more favorable than NexImmune.
NexImmune's return on equity of -247.17% beat Mustang Bio's return on equity.
NexImmune is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.
9.9% of NexImmune shares are held by institutional investors. Comparatively, 10.0% of Mustang Bio shares are held by institutional investors. 19.4% of NexImmune shares are held by insiders. Comparatively, 2.1% of Mustang Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Mustang Bio beats NexImmune on 9 of the 13 factors compared between the two stocks.
Get NexImmune News Delivered to You Automatically
Sign up to receive the latest news and ratings for NEXI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NEXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NexImmune Competitors List
Related Companies and Tools
